ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Undifferentiated Pleomorphic SarcomaMyxofibrosarcoma
Interventions
BIOLOGICAL

Envafolimab

PD-L1 single domain antibody for subcutaneous injection.

DRUG

Ipilimumab

CTLA-4 monoclonal antibody

Trial Locations (30)

10027

Columbia University, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15260

University of Pittsburgh, Pittsburgh

19106

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University (Sidney Kimmel Cancer Center), Philadelphia

21218

Johns Hopkins University, Baltimore

23284

Virginia Commonwealth University, Richmond

27708

Duke University, Durham

32224

Mayo Clinic, Jacksonville, Jacksonville

33136

University of Miami, Miami

33612

H. Lee Moffitt Cancer Center, Tampa

37235

Vanderbilt University, Nashville

43210

Ohio State University, Columbus

44106

University Hospitals, Cleveland

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Wauwatosa

55901

Mayo Clinic Rochester, Rochester

60208

Northwestern University, Evanston

63130

Washington University in St. Louis, St Louis

80045

University of Colorado, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

85721

University of Arizona, Tucson

89106

Cleveland Clinic, Cleveland

90095

University of California, Los Angeles, Los Angeles

90403

Sarcoma Oncology Research Center, Santa Monica

94305

Stanford University, Stanford

98109

Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

SW3 6JJ

Royal Marsden, London

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT04480502 - ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | Biotech Hunter | Biotech Hunter